文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

A-I/II类清道夫受体和CD36是负责摄取修饰的低密度脂蛋白从而导致巨噬细胞脂质负荷的主要受体。

Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages.

作者信息

Kunjathoor Vidya V, Febbraio Maria, Podrez Eugene A, Moore Kathryn J, Andersson Lorna, Koehn Stephanie, Rhee Jeongmi S, Silverstein Roy, Hoff Henry F, Freeman Mason W

机构信息

Lipid Metabolism Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

出版信息

J Biol Chem. 2002 Dec 20;277(51):49982-8. doi: 10.1074/jbc.M209649200. Epub 2002 Oct 9.


DOI:10.1074/jbc.M209649200
PMID:12376530
Abstract

Modification of low density lipoprotein (LDL) can result in the avid uptake of these lipoproteins via a family of macrophage transmembrane proteins referred to as scavenger receptors (SRs). The genetic inactivation of either of two SR family members, SR-A or CD36, has been shown previously to reduce oxidized LDL uptake in vitro and atherosclerotic lesions in mice. Several other SRs are reported to bind modified LDL, but their contribution to macrophage lipid accumulation is uncertain. We generated mice lacking both SR-A and CD36 to determine their combined impact on macrophage lipid uptake and to assess the contribution of other SRs to this process. We show that SR-A and CD36 account for 75-90% of degradation of LDL modified by acetylation or oxidation. Cholesteryl ester derived from modified lipoproteins fails to accumulate in macrophages taken from the double null mice, as assessed by histochemistry and gas chromatography-mass spectrometry. These results demonstrate that SR-A and CD36 are responsible for the preponderance of modified LDL uptake in macrophages and that other scavenger receptors do not compensate for their absence.

摘要

低密度脂蛋白(LDL)的修饰可导致这些脂蛋白通过一类被称为清道夫受体(SRs)的巨噬细胞跨膜蛋白被大量摄取。先前已表明,两种SR家族成员SR-A或CD36中的任何一种发生基因失活,均可在体外减少氧化LDL的摄取,并减少小鼠的动脉粥样硬化病变。据报道,其他几种SR也可结合修饰的LDL,但其对巨噬细胞脂质蓄积的作用尚不确定。我们培育出同时缺乏SR-A和CD36的小鼠,以确定它们对巨噬细胞脂质摄取的联合影响,并评估其他SR在这一过程中的作用。我们发现,SR-A和CD36占乙酰化或氧化修饰LDL降解的75%-90%。通过组织化学和气相色谱-质谱分析评估,来自修饰脂蛋白的胆固醇酯未能在双敲除小鼠的巨噬细胞中蓄积。这些结果表明,SR-A和CD36是巨噬细胞摄取修饰LDL的主要原因,且其他清道夫受体无法弥补它们的缺失。

相似文献

[1]
Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages.

J Biol Chem. 2002-12-20

[2]
Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein.

J Biol Chem. 2003-11-28

[3]
High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II.

J Biol Chem. 1997-5-16

[4]
Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36.

J Biol Chem. 1997-8-22

[5]
Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36.

Arterioscler Thromb Vasc Biol. 2001-6

[6]
Scavenger receptors and oxidized low density lipoproteins.

Clin Chim Acta. 1999-8

[7]
Low-density lipoprotein from apolipoprotein E-deficient mice induces macrophage lipid accumulation in a CD36 and scavenger receptor class A-dependent manner.

Arterioscler Thromb Vasc Biol. 2005-1

[8]
Alpha-tocopherol decreases CD36 expression in human monocyte-derived macrophages.

J Lipid Res. 2001-4

[9]
A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions.

J Biol Chem. 2002-10-11

[10]
Synergically increased expression of CD36, CLA-1 and CD68, but not of SR-A and LOX-1, with the progression to foam cells from macrophages.

J Atheroscler Thromb. 2002

引用本文的文献

[1]
Macrophage-Targeted Nanomedicine for the Treatment of Atherosclerosis.

Int J Nanomedicine. 2025-8-25

[2]
Oxidized phospholipid damage signals as modulators of immunity.

Open Biol. 2025-7

[3]
The Effect of Kidney Transplantation and Immunosuppressive Therapy on Adipose Tissue Content and Adipocytokine Plasma Concentration-Preliminary Study.

Curr Issues Mol Biol. 2025-4-7

[4]
Gut microbiota's role in heart failure.

Heart Fail Rev. 2025-7-9

[5]
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?

Curr Atheroscler Rep. 2025-7-5

[6]
Macrophage Deficiency of Sorting Nexin 25 Suppress Plaque Formation in Atherosclerotic Lesions in Mice.

Acta Histochem Cytochem. 2025-4-26

[7]
Foamy macrophages in atherosclerosis: unraveling the balance between pro- and anti-inflammatory roles in disease progression.

Front Cardiovasc Med. 2025-5-2

[8]
The Role of Ubiquitination on Macrophages in Cardiovascular Diseases and Targeted Treatment.

Int J Mol Sci. 2025-4-30

[9]
USP22 enhances atherosclerotic plaque stability and macrophage efferocytosis by stabilizing PPARγ.

Commun Biol. 2025-4-29

[10]
Effects of Chinese Medicine on modulating interleukin-17-regulated macrophages in coronary heart disease.

Front Pharmacol. 2025-4-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索